Inzy stock forecast.

The average price target for Inozyme Pharma's stock set by recognized analysts recently is $23.00, which would result in a potential upside of approximately …Earnings for Incyte are expected to grow by 28.00% in the coming year, from $3.00 to $3.84 per share. Incyte has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 6th, 2024 based off prior year's report dates. Read More.Find the latest Pop Culture Group Co., Ltd (CPOP) stock quote, history, news and other vital information to help you with your stock trading and investing.Market cap is calculated by taking a company's price per share and multiplying it by the company's total number of shares outstanding. $12.95B. -12.7%. Market Cap / Employee. The market cap of a ... The company’s stock had a trading volume of 1,882,507 shares, compared to its average volume of 1,653,219. The company’s fifty day simple moving average is $55.35 and its 200-day simple moving ...

Price Prediction Incyte price predictions from 2023 to 2027. Gain insights into monthly forecasts, trends, and analyses to make informed investment decisions.Find the latest Plus Therapeutics, Inc. (PSTV) stock quote, history, news and other vital information to help you with your stock trading and investing.TipRanks | Stock Market Research, News and Analyst Forecasts ...

Evogene Ltd. -1.07%. $30.17M. BLFS | Complete BioLife Solutions Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Find the latest Spyre Therapeutics, Inc. (AGLE) stock quote, history, news and other vital information to help you with your stock trading and investing.

Nov 22, 2023 · Incyte Corp (INCY) Stock Forecast: Potential 33% Increase According to Analysts. On November 22, 2023, Incyte Corp (INCY) stock had a median target price forecast of $71.00, according to 18 analysts surveyed by CNN Money. The high estimate for the stock price was $93.00, while the low estimate was $58.00. Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level. Try it Free. Find the latest Incyte Corporation (INCY) stock forecast based ...Upgrade to Premium to see how . INZY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks. Try It for Just $1. ... Inozyme Pharma 's market cap is calculated by multiplying INZY's current stock price of $3.93 by INZY's total outstanding shares of 61,760,748.According to the issued ratings of 19 analysts in the last year, the consensus rating for Incyte stock is Hold based on the current 1 sell rating, 10 hold ratings and 8 buy ratings for INCY. The average twelve-month price prediction for Incyte is $79.94 with a high price target of $100.00 and a low price target of $61.00.Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level. Try it Free. Find the latest Incyte Corporation (INCY) stock forecast based ...

Earnings Date. Feb 05, 2024 - Feb 09, 2024. Forward Dividend & Yield. N/A (N/A) Ex-Dividend Date. N/A. 1y Target Est. 74.41. Fair Value is the appropriate price for the shares of a company, based ...

We've seen plenty of personal finance tools designed to help you track what you're spending, but web site PocketSmith is an impressive new web-based personal finance tool with an emphasis on forecasting your financial future. We've seen ple...The firm owned 605,555 shares of the company’s stock after selling 69,848 ... Equities analysts forecast that Dynatrace, Inc. will post 0.58 ... INZY) Rock Springs Capital Management ...Find the latest eFFECTOR Therapeutics, Inc. (EFTR) stock quote, history, news and other vital information to help you with your stock trading and investing.Inozyme Pharma stock forecast report. View INZY price target, analyst ratings, upgrades & downgrades predictions, and buy or a sell data.Aug 9, 2023 · For the current quarter, INZY is expected to report an EPS forecast of -$0.45. In terms of annual financials, INZY reported an annual revenue of $0.00 for the last year and an annual profit of -$67.1 million. INZY Stock Shows Promising Performance on August 9, 2023: Optimistic Price Forecasts and Unanimous Buy Rating. INZY stock, belonging to ... INZY Overview Stock Screener Earnings Calendar Sectors Nasdaq | INZY U.S.: Nasdaq Inozyme Pharma Inc. Watch NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 6:44 p.m. EST...President exercised options and sold US$65k worth of stock Jun 26. Inozyme Pharma, Inc. Announces Acceptance of First European Clinical Trial Application …

Nov 29, 2023 · See the latest Inozyme Pharma Inc Ordinary Shares stock price (INZY:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Get the latest Inozyme Pharma Inc (INZY) stock quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. See the company's financial results, market news, and earnings per share for the fiscal Q2 2023 ended 6/30/23. According to the issued ratings of 4 analysts in the last year, the consensus rating for Inozyme Pharma stock is Buy based on the current 4 buy ratings for INZY. The average twelve-month price prediction for Inozyme Pharma is $15.00 with a high price target of $23.00 and a low price target of $6.00. Learn more on INZY's analyst rating history.The core CPI, excluding food and energy, rose 4.8% from the prior year, also slowing from 5.3% in May and below the consensus forecast. The Dow rose 0.8%, the S&P 1.0%, and the Nasdaq 1.4%. Crude ... INZY Signals & Forecast The Inozyme Pharma, Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.

Incyte Corp. Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib).

Is Inozyme Pharma Stock Undervalued? The current Inozyme Pharma share price is $3.85. The Score for INZY is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. INZY is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.4 brokers have issued 1-year target prices for Inozyme Pharma's stock. Their INZY share price targets range from $6.00 to $23.00. On average, they predict the …Nov 20, 2023 · Target values for the price of one Incyte share for Jan 2025. The weighted average target price per Incyte share in Jan 2025 is: 59.50. In Jan, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 7.054% volatility is expected. Pessimistic target level: 56.44. Optimistic target level: 60.73. Incyte Corp (INCY) $53.74 0.34 (0.64%) 13:00 EST INCY Stock Quote Delayed 30 Minutes.Stock analysis for Inozyme Pharma Inc (INZY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.Nasdaq Futures -44.75(-0.28%) Russell 2000 Futures 1,798.80 -12.20(-0.67%) Crude Oil 74.30 -1.24(-1.64%) Gold 2,013.20 +10.20(+0.51%) Inozyme Pharma, Inc. (INZY) NasdaqGS - NasdaqGS Real Time... Inozyme Pharma Stock Chart and Share Price Forecast, Short-Term "INZY" Stock Prediction for Next Days and Weeks Walletinvestor.com Inozyme Pharma Inc (INZY) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024Get The Latest BRID Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. Skip to main content. S&P 500 4,594.63. DOW 36,245.50. QQQ 389.94. ... Bread Frozen Dough Market Analysis by Top Companies and Forecast 2031. See More Headlines .

Analyst Forecast According to 16 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $79.25, which is an increase of 46.71% from the latest price.

Incyte Corp Revenue Forecast for 2023 - 2025 - 2030. Incyte Corp's Revenue has seen impressive growth In the last three years, rising from $2.16B to $3.39B – a growth of 57.25%. In the next year, analysts believe that Revenue will reach $3.93B – an increase of 15.71%. For the next eight years, the forecast is for Revenue to grow by 16.18%.

Find the latest SciSparc Ltd. (SPRC) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest Moleculin Biotech, Inc. (MBRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest Phathom Pharmaceuticals, Inc. (PHAT) stock quote, history, news and other vital information to help you with your stock trading and investing.Incyte Corp. Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib).Find the latest Incyte Corporation (INCY) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceNov 22, 2023 · Incyte Corp (INCY) Stock Forecast: Potential 33% Increase According to Analysts. On November 22, 2023, Incyte Corp (INCY) stock had a median target price forecast of $71.00, according to 18 analysts surveyed by CNN Money. The high estimate for the stock price was $93.00, while the low estimate was $58.00. See Full INZY Report. INZY stock closed at $4.37 and is up $0.21 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. INZY has a strong overall score of 92 meaning the stock holds a better value than 92% of stocks at its current price.Mar. 23, 2023, 11:25 AM. Needham analyst Joseph Stringer reiterated a Buy rating on Inozyme Pharma ( INZY – Research Report) today and set a price target of $23.00. The company’s shares opened ...

Nov 22, 2023 · Incyte Corp (INCY) Stock Forecast: Potential 33% Increase According to Analysts. On November 22, 2023, Incyte Corp (INCY) stock had a median target price forecast of $71.00, according to 18 analysts surveyed by CNN Money. The high estimate for the stock price was $93.00, while the low estimate was $58.00. TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comOpen $1.8900. Day Range 1.8200 - 1.9297. 52 Week Range 0.5800 - 6.7700. Market Cap $296.38M. Shares Outstanding 156.82M. Public Float 46.42M. Beta 0.48. Rev. per Employee $238.76K. P/E Ratio N/A.Nov 24, 2023 · Stock Price Forecast. According to 16 stock analysts, the average 12-month stock price forecast for Incyte stock is $79.25, which predicts an increase of 47.47%. The lowest target is $60 and the highest is $100. On average, analysts rate Incyte stock as a buy. Instagram:https://instagram. splunk inc stockflorida hurricane insurance companiesbest platform to buy golddental plans that cover root canals and crowns For Sorrento Therapeutics stock forecast for 2023, 8 predictions are offered for each month of 2023 with average Sorrento Therapeutics stock forecast of $0.76, a high forecast of $1.2, and a low forecast of $0.36. The average Sorrento Therapeutics stock forecast 2023 represents a 127.59% increase from the last price of $0.332199990749359. Find the latest SciSparc Ltd. (SPRC) stock quote, history, news and other vital information to help you with your stock trading and investing. is spacex going publichumana c550 dental plan On December 4, 2023, Incyte (NASDAQ:INCY) received a significant boost as Guggenheim analyst Michael Schmidt upgraded the company’s rating from Neutral to Buy. Schmidt set a price target of $86.00 for the stock, indicating a positive outlook on Incyte’s performance. This upgrade aligns with the consensus among analysts, who have an average ... 1 month t bills Nov 24, 2023 · Stock Price Forecast. According to 16 stock analysts, the average 12-month stock price forecast for Incyte stock is $79.25, which predicts an increase of 47.47%. The lowest target is $60 and the highest is $100. On average, analysts rate Incyte stock as a buy. Find the latest Institutional Holdings data for Inozyme Pharma, Inc. Common Stock (INZY) at Nasdaq.com.Incyte Corp. Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib).